In dispersed acini from dog pancreas, exogenous derivatives of cAMP stimulated the amylase release; 8-Br-cAMP was a more potent stimulant than Bt2-cAMP, and induced a potentiation of the amylase release stimulated by cerulein. Both secretin and vasoactive intestinal peptide (VIP), increased cellular cAMP, with a greater potency for secretin, and supra-maximal concentration of secretin plus VIP increased cellular cAMP to the same degree as that obtained with secretin alone. 125I-VIP-binding studies showed that in dog pancreatic acini there is a 95 % decrease in the number of VIP-preferring receptors with minor changes in receptor affinity as compared to guinea-pig pancreas. The absence of effect between secretin or VIP and cerulein in stimulating amylase release could likely be explained by the low number in VIP-preferring receptors on dog pancreatic acini.

Journal Section:
Original Paper
Keywords:
Dog, Pancreatic acini, Amylase release, cAMP, Secretin, Vasoactive intestinal peptide, Cerulein, Potentiation, Exogenous derivatives of cAMP
This content is only available via PDF.
© 1983 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
1983
You do not currently have access to this content.